RE: ** Technical / Fundamental Analysis on ONC **"Given that the market for Reolysin is significantly greater than the HIV and hepatitis markets, I think that any take-over of ONC would not be for less than US$4.5 Billion resulting in a price of at least US$157.00/share for ONC or C$208.00 "
If a big pharma, or a partner, saw the potential in ONC, providing the results verified it, they would move heaven and earth to aquire it at the lowest possible price. Why do you think our previous partner tried to break ONC's patents. The only protection the shareholders have is that positive news would drive the price up to levels that would preclude a very cheap takeover. Even still, the pharma would still get the company for LESS than it would be worth. In the overall scheme of things the lowly shareholder is at the bottom of the feeding chain. I believe that ,if ONC achieves it's potential, we will all get a very good return for our investment but it will be less than what the partner will get.